Ruggeri, Matteo, Alessandro Signorini, and Silvia Caravaggio. 2023. “Casirivimab and Imdevimab: Cost-Effectiveness Analysis of the Treatment Based on Monoclonal Antibodies on Outpatients with Covid-19.” PLOS ONE 18 (2): e0279022. https://doi.org/10.1371/journal.pone.0279022.
Ruggeri, Matteo, Alessandro Signorini, Silvia Caravaggio, and Flaminia Coluzzi. 2022. “Tapentadolo versus Ossicodone/Naloxone nelle formulazioni branded e generiche per Il trattamento del dolore muscoloscheletrico: Analisi aggiornata del rapporto costo-efficacia.” Giornale Del Medico Online, 1–8.
Ruggeri, Matteo, Alessandro Signorini, Silvia Caravaggio, P. F. Morel, F. Starace, and C. Mencacci. 2022. “Depressione resistente al trattamento; Un’indagine valuta l’impatto economico in Italia.” Medico e Paziente, Medicina Approfondimenti, 12–17.
Ruggeri, Matteo, Alessandro Signorini, Silvia Caravaggio, João Rua, Nuno Luís, Sandra Braz, and Filipa Aragão. 2022. “Estimation Model for Healthcare Costs and Intensive Care Units Access for Covid-19 Patients and Evaluation of the Effects of Remdesivir in the Portuguese Context: Hypothetical Study.” Clinical Drug Investigation 42 (4): 345–54. https://doi.org/10.1007/s40261-022-01128-8.
Ruggeri, Matteo, Alessandro Signorini, Silvia Caravaggio, Basem Alraddadi, Alaa Alali, James Jarrett, Sam Kozma, Camille Harfouche, and Tariq Al Musawi. 2022. “Modeling the Potential Impact of Remdesivir Treatment for Hospitalized Patients with COVID-19 in Saudi Arabia on Healthcare Resource Use and Direct Hospital Costs: A Hypothetical Study.” Clinical Drug Investigation 42 (8): 669–78. https://doi.org/10.1007/s40261-022-01177-z.
Ruggeri, Matteo, Alessandro Signorini, Silvia Caravaggio, and F. Ruggeri. 2021. “Analisi costo-efficacia del Tapentadolo versus Ossicodone/Naloxone – nelle formulazioni branded e generiche – su pazienti con dolore muscoloscheletrico.” Italian Journal of Preventive, Diagnostic and Therapeutic Medicine 4 (1).
Ruggeri, Matteo, Alessandro Signorini, Silvia Caravaggio, Costanza Santori, Francesco Rosiello, and Flaminia Coluzzi. 2021. “Cost-Effectiveness Analysis of Tapentadol Versus Oxycodone/Naloxone in Both Branded and Generic Formulations in Patients with Musculoskeletal Pain.” Clinical Drug Investigation 41 (10): 875–83. https://doi.org/10.1007/s40261-021-01074-x.
Ruggeri, Matteo, Alessandro Signorini, Silvia Caravaggio, Basem Alraddadi, Alaa Alali, Sam Kozma, Camille Harfouche, and Tariq AlMusawi. 2021. “PCO-003 - The Estimation of Direct Hospital Costs and Intensive Care Units (ICU) Admissions for COVID-19 Patients and the Assessment of the Impact of Remdesivir Administration in the Saudi Arabian Context.” International Journal of Antimicrobial Agents, Abstracts from the 13th International Symposium on Antimicrobial Agents and Resistance (ISAAR 2021), 58 (September): 21003484. https://doi.org/10.1016/j.ijantimicag.2021.106421.77.
Signorini, Alessandro. 2020a. “Cashback Programs in Ecommerce Retailers: The Choice between Pure Cashback and Donation.” In Sinergie-SIMA 2020 Conference Proceedings. Pisa.
Signorini, Alessandro. 2020b. “Social Spin-Offs from Established Non-Profit Organizations; Factors Influencing the Behavior of Corporate Donors.” In Sinergie-SIMA 2020 Conference Proceedings. Pisa.
Ruggeri, Matteo, Alessandro Signorini, Carlo Drago, Francesco Rosiello, and Marco Marchetti. 2020. “Modello di stima dei costi sanitari e della capacity delle terapie intensive in Italia nel trattamento di pazienti affetti da COVID-19: Valutazione dell’impatto di remdesivir.” AboutOpen 7 (1): 1–8. https://doi.org/10.33393/abtpn.2020.2213.
Signorini, Alessandro, and G. Torosantucci. 2019. “Marketing Sustainable Financial Products to Specific Target Segments; the Case of the Italian Market.” In Sinergie-SIMA 2019 Conference Proceedings. Roma.
Signorini, Alessandro, and Stan Paliwoda. 2012. “Previous Alliance Relationships and Their Effects on Future Acquisition Performance: The Case of the Airline Industry.” Competitive Paper.
Signorini, Alessandro, Hubert Rienzner, and Harald Pechlaner. 2002. L’ impatto di una low-cost-airline: Conseguenze per un aeroporto regionale, lo sviluppo turistico ed economico locale. Bozen: Europäische Akademie - EURAC.